151 related articles for article (PubMed ID: 29924240)
21. Patient profile and treatment satisfaction of Brazilian leprosy patients in a clinical trial of uniform six-month multidrug therapy (U-MDT/CT-BR).
Ferreira IP; Buhrer-Sékula S; De Oliveira MR; Gonçalves Hde S; Pontes MA; Penna ML; Cruz R; Penna GO
Lepr Rev; 2014 Dec; 85(4):267-74. PubMed ID: 25675651
[TBL] [Abstract][Full Text] [Related]
22. OFLOXACIN multicentre trial in MB leprosy FUAM-Manaus and ILSL-Bauru, Brazil.
Cunha Mda G; Virmond M; Schettini AP; Cruz RC; Ura S; Ghuidella C; Viana Fdos R; Avelleira JC; Campos AA; Filho B
Lepr Rev; 2012 Sep; 83(3):261-8. PubMed ID: 23356027
[TBL] [Abstract][Full Text] [Related]
23. Field trial on efficacy of supervised monthly dose of 600 mg rifampin, 400 mg ofloxacin and 100 mg minocycline for the treatment of leprosy; first results.
Mane I; Cartel JL; Grosset JH
Int J Lepr Other Mycobact Dis; 1997 Jun; 65(2):224-9. PubMed ID: 9251595
[TBL] [Abstract][Full Text] [Related]
24. Hepatic and haematological adverse reactions associated with the use of multidrug therapy in leprosy--a five year retrospective study.
Kaluarachchi SI; Fernandopulle BM; Gunawardane BP
Indian J Lepr; 2001; 73(2):121-9. PubMed ID: 11579648
[TBL] [Abstract][Full Text] [Related]
25. Feasibility of multidrug therapy (MDT) in Hansen's disease in an urban population--Curupaiti State Hospital, Rio de Janeiro, Brazil.
Andrade VL; Marques AB; da Cunha LH; Avelleira JR
Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):435-40. PubMed ID: 3655459
[TBL] [Abstract][Full Text] [Related]
26. Dapsone syndrome in Vanuatu: a high incidence during multidrug treatment (MDT) of leprosy.
Reeve PA; Ala J; Hall JJ
J Trop Med Hyg; 1992 Aug; 95(4):266-70. PubMed ID: 1386634
[TBL] [Abstract][Full Text] [Related]
27. Dapsone hypersensitivity syndrome in an adolescent during treatment during of leprosy.
Bucaretchi F; Vicente DC; Pereira RM; Tresoldi AT
Rev Inst Med Trop Sao Paulo; 2004; 46(6):331-4. PubMed ID: 15654479
[TBL] [Abstract][Full Text] [Related]
28. Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil.
Maia MV; Cunha Mda G; Cunha CS
An Bras Dermatol; 2013; 88(2):205-10. PubMed ID: 23739719
[TBL] [Abstract][Full Text] [Related]
29. Seventy years of evidence on the efficacy and safety of drugs for treating leprosy: a network meta-analysis.
Yang J; Kong J; Li B; Ji Z; Liu A; Chen J; Liu M; Fan Y; Peng L; Song J; Wu X; Gao L; Ma W; Dong Y; Luo S; Bao F
J Infect; 2023 Apr; 86(4):338-351. PubMed ID: 36796681
[TBL] [Abstract][Full Text] [Related]
30. Influence of acetylator phenotype on the haematological and biochemical effects associated with dapsone in leprosy patients.
Queiroz RH; Souza AM; Melchior E; Gouveia EG; Carvalho D
Lepr Rev; 1997 Sep; 68(3):212-7. PubMed ID: 9364821
[TBL] [Abstract][Full Text] [Related]
31. Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation.
Schalcher TR; Borges RS; Coleman MD; Batista Júnior J; Salgado CG; Vieira JL; Romão PR; Oliveira FR; Monteiro MC
PLoS One; 2014; 9(1):e85712. PubMed ID: 24465659
[TBL] [Abstract][Full Text] [Related]
32. Comparative study of short term results in two multidrug regimens in multibacillary leprosy.
Singh RP; Tiwari VD; Chattopadhyay SP
Indian J Lepr; 1993; 65(2):173-80. PubMed ID: 8345231
[TBL] [Abstract][Full Text] [Related]
33. International open trial of uniform multi-drug therapy regimen for 6 months for all types of leprosy patients: rationale, design and preliminary results.
Kroger A; Pannikar V; Htoon MT; Jamesh A; Katoch K; Krishnamurthy P; Ramalingam K; Jianping S; Jadhav V; Gupte MD; Manickam P
Trop Med Int Health; 2008 May; 13(5):594-602. PubMed ID: 18346026
[TBL] [Abstract][Full Text] [Related]
34. [Guideline for the treatment of Hansen's disease in Japan (Second edition)].
Goto M; Nogami R; Hatano K; Okano Y; Ishii N; Gidoh M; Ishida Y; Ozaki M;
Nihon Hansenbyo Gakkai Zasshi; 2006 Sep; 75(3):191-226. PubMed ID: 17037376
[TBL] [Abstract][Full Text] [Related]
35. Comparative study of uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation.
Rao PN; Suneetha S; Pratap DV
Lepr Rev; 2009 Jun; 80(2):143-55. PubMed ID: 19743618
[TBL] [Abstract][Full Text] [Related]
36. Aplastic anaemia associated with multidrug therapy (dapsone, rifampicin and clofazimine) in a patient with lepromatous leprosy.
Goulart IM; Reis AC; De Rezende TM; Borges AS; Ferreira MS; Nishioka SA
Lepr Rev; 2005 Jun; 76(2):167-9. PubMed ID: 16038251
[No Abstract] [Full Text] [Related]
37. Twenty five years follow up of MB leprosy patients retreated with a modified MDT regimen after a full course of dapsone mono-therapy.
Jing Z; Zhang R; Zhou D; Chen J
Lepr Rev; 2009 Jun; 80(2):170-6. PubMed ID: 19743621
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy of leprosy.
Biswas SK;
J Indian Med Assoc; 2004 Dec; 102(12):695-6, 698. PubMed ID: 15871354
[TBL] [Abstract][Full Text] [Related]
39. Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur).
Singh H; Nel B; Dey V; Tiwari P; Dulhani N
Lepr Rev; 2011 Mar; 82(1):17-24. PubMed ID: 21644468
[TBL] [Abstract][Full Text] [Related]
40. Dapsone syndrome with acute renal failure during leprosy treatment: case report.
Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Fontes CJ
Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
